Form 4: Mersana Therapeutics Acquired, Director Dere Reports Holdings

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc., with Director Willard H. Dere reporting the disposition of his common stock and stock options as part of the merger.

Summary

• Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc. through its subsidiary, Emerald Merger Sub, Inc., effective January 6, 2026.
• The merger involved a tender offer where shares of Mersana's common stock were exchanged for an Offer Price consisting of $25.00 per share in upfront cash and one non-tradeable contingent value right (CVR).
• Each CVR represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash.
• Director Willard H. Dere reported the disposition of 1,567 shares of common stock and all his stock options as a result of the merger.
• Stock options with an exercise price less than the $25.00 Upfront Cash Consideration (Cash-Out Options) became fully vested, were cancelled, and converted into the right to receive the Offer Price minus their exercise price.
• Stock options with an exercise price equal to or greater than the $25.00 Upfront Cash Consideration (OTM Options) became fully vested and exercisable for a limited period, after which any unexercised options were cancelled without consideration.
• Following the reported transactions, Willard H. Dere beneficially owns 0 shares of common stock and 0 derivative securities.

Sentiment

Score: 5

Explanation: The filing is a factual report of a completed merger and the resulting changes in beneficial ownership for a director. It does not convey a positive or negative sentiment about ongoing operations, but rather the execution of a defined corporate action.

Positives

• Shareholders, including Director Dere, received an upfront cash consideration of $25.00 per share.
• Shareholders also received contingent value rights (CVRs) with potential future payments of up to $30.25 per CVR, offering additional upside.
• Cash-Out Options held by the director were converted into cash, providing liquidity.

Negatives

• Out-of-the-money (OTM) stock options, which had exercise prices significantly higher than the upfront cash consideration, were cancelled if not exercised, likely resulting in no value for the holders of these specific options.
• The company is now a wholly-owned subsidiary, ending its independent public trading status.

Risks

• The contingent value rights (CVRs) are non-tradeable and their value is dependent on the achievement of specified milestones, which may or may not occur.
• OTM options that were not exercised by the Last Exercise Date were cancelled and ceased to exist, resulting in no consideration for those specific options.

Future Outlook

Mersana Therapeutics, Inc. is now a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. The future financial performance and strategic direction will be determined by the parent company. The potential for additional value for former Mersana shareholders lies in the achievement of the contingent milestones associated with the CVRs.

Industry Context

This transaction represents a strategic acquisition within the biotechnology and pharmaceutical sector, where larger companies often acquire smaller, innovative firms to expand their pipeline or technology base. The use of contingent value rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks and rewards.

Stakeholder Impact

• Shareholders of Mersana Therapeutics, Inc. received cash and CVRs for their shares, concluding their investment in the independent entity.
• Employees who held stock options were impacted by the conversion or cancellation of their options based on the merger terms.
• Mersana Therapeutics, Inc. now operates as a wholly-owned subsidiary, integrating into Day One Biopharmaceuticals, Inc.'s corporate structure.

Next Steps

• Monitoring the achievement of specified milestones for the contingent value rights (CVRs) to determine if additional payments will be made to former Mersana shareholders.

Key Dates

Keywords

Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Options, Insider Transaction, Form 4, Mersana Therapeutics, Day One Biopharmaceuticals